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Assessment, classification and treatment of
calcinosis as a complication of juvenile
dermatomyositis: a survey of pediatric
rheumatologists by the childhood arthritis
and rheumatology research alliance
(CARRA)
A. B. Orandi1*, K. W. Baszis1, V. R. Dharnidharka2, A. M. Huber3, and M. F. Hoeltzel4 for the CARRA Juvenile Myositis
subgroup

Abstract
Background: There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes.
Current knowledge of treatment outcomes is confined to small series and case reports. We describe physician
perspectives toward diagnostic approach, classification and treatment directly targeting calcinosis, independent
of overall JDM therapy.
Methods: An electronic survey of 22 questions was organized into sections regarding individual practices of
assessment, classification and treatment of calcinosis, including perceived successes of therapies. Invitations to
complete the survey voluntarily and anonymously were sent to CARRA physician members and the Pediatric
Rheumatology Bulletin Board, an electronic list-serv. Results were analyzed by descriptive statistics and chi-square
analyses.
Results: Of 139 survey responses, 118 were included in analysis. Of these, 70% were based in the USA and
88 (75%) were CARRA members. Only 17% of responders have seen more than 20 cases of calcinosis, and
only 28% perform screening imaging studies on new JDM diagnoses. Increasing systemic immunosuppression
is first-line therapy for 67% of respondents. Targeted therapy against calcinosis is most often instituted for
symptomatic patients. IVIG and bisphosphonates are most frequently used and considered most successful,
but many other agents are used. Experienced physicians are more likely to use bisphosphonates, calcium
channel blockers and topical sodium thiosulfate (p< 0.002 or lower).
Conclusions: Coexisting JDM disease activity influences whether calcinosis is considered active disease or
targeted directly. Experience treating JDM-related calcinosis is low, as are rates of formal screening for calcinosis.
Experienced physicians are more likely to use non-immunosuppressive treatments.
Keywords: Juvenile dermatomyositis, Calcinosis, Survey, CARRA, Treatment
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Background
Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood, though still rare,
with an estimated incidence of 3.2 children per million
per year [1]. The cardinal features include proximal
muscle weakness and characteristic rash, but multiple
other organs can be involved and contribute to morbidity and mortality, including the gastrointestinal, cardiac
and pulmonary systems. With improved disease understanding and treatments, mortality has been significantly
reduced [2, 3], but long-term morbidity and treatment
toxicity remain as challenges [4]. A prominent contributor to overall morbidity is calcinosis, the accumulation
of dystrophic carbonate apatite [5] in skin and soft tissues,
both a trademark and feared complication whose presence
has been unyielding in the face of other advances. Its staying power is owed to an incomplete understanding of both
its pathogenesis and actionable risk factors that could support alterations in management [6–8]. Although it is reported that early aggressive treatment can prevent the
development of calcinosis [9–11], the incidence continues
to remain at an estimated 30–40% of patients through
various cohort and registry studies [12–15].
To date, there are no randomized controlled trials or
standardized recommendations for the treatment of calcinosis as it occurs in JDM. Many therapeutic agents
with different mechanisms of action have been used,
with none showing a consistently positive response. In a
recent review, nearly 20 different therapies have been
described to have positive responses in published cases
[15]. Further complicating the management of this condition are the varying phenotypes [16, 17], such as circumscripta, tumoral, universalis and exoskeleton lesions,
as well as the inconsistent timing of calcinosis respective
to other disease features [18–20]. While the ultimate
goal is to improve outcomes of patients with calcinosis,
our aim is to describe the current practices of pediatric
rheumatologists, including approaches to assessment, classification and treatment, thereby consolidating consensus
opinions that can be formally studied. This technique has
been successfully implemented in the overall treatment of
JDM by the Childhood Arthritis and Rheumatology Research Alliance (CARRA), whose consensus treatment
plans are currently being instituted and analyzed [21–24].
Methods
Using the REDCap platform, an electronic survey was
created, consisting of 22 questions divided into four sections: demographic characteristics, assessment, classification and treatment (Additional file 1). For phenotype
classification questions, calcinosis phenotypes were described as follows: Circumscripta; superficial plaques or
nodules. Tumoral; larger nodules that extend into deeper layers. Universalis; involvement along fascial planes
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of muscles or tendons. Exoskeleton; hardened deposits
over a surface area. For treatment choice-related questions, ‘immunomodulatory’ agents are those which directly
suppress or modulate the immune system whereas ‘alternative’ agents are those with non-immunosuppressive actions, such as altering calcium and/or phosphorous
metabolism. Any treatment success-related questions are
defined as physician perceived success. For questions related to situational treatment, ‘targeted treatment’ refers to
a treatment chosen for calcinosis specifically and not any
other co-existing JDM disease activity.
Physicians, including fellows-in-training, who specialize
in pediatric, adult, combined rheumatology or immunology were invited by e-mail to complete the survey. Participants were asked to respond according to their
personal experience, not that of institution or group practices or based on the medical literature. Respondents were
asked to quantify their experience by years of practice and
lifetime cases seen of JDM-associated calcinosis. In
January 2016, the survey was electronically sent to
303 voting and trainee physician members of CARRA;
a North American collaborative research organization
and to the Pediatric Rheumatology Bulletin Board, an
international electronic list-serv. Members of CARRA
who are also on the Bulletin Board were asked to
only respond once. All respondents voluntarily and
anonymously completed the survey.
Physicians of different experience levels, determined
by years of practice and by number of cases seen, were
captured, and the discrepancy between experience levels
highlighted an important finding: because of the rare incidence of JDM, even some seasoned physicians had
seen few cases of calcinosis. Because of this finding, the
number of cases seen was used as the metric of experience instead of years in practice. Therefore, a physician
who is experienced with treating JDM-associated calcinosis was defined as having seen greater than 10 cases.
The results of the survey were analyzed by descriptive
statistics and chi-square analyses for comparisons between physicians who have seen greater and less than 10
cases. Analysis was performed using IBM SPSS Statistics
(version 24), Armonk, NY.

Results
A total of 139 individuals accessed the survey with 5 individuals excluded for not answering any questions. Four
respondents were excluded for no personal experience
with JDM patients less than 21 years of age, and 3 were
excluded for no personal experience treating JDMassociated calcinosis. An additional 9 were excluded for
only completing the demographic section. A total of 118
respondents completed at least one full survey section in
addition to demographic characteristics, qualifying for
analysis, with a total of 103 respondents completing the
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survey entirely (Fig. 1). CARRA members constituted
75% (88/118) of the analyzed responses and based on
the number of CARRA members who received the
survey invitation the CARRA response rate is estimated at 30% (88/303).
Less than 5% of respondents practiced something
other than pediatric rheumatology. Approximately
70% of respondents were based in the United States,
with Europe the next most common location at 14%.
The distribution of experience by years showed nearly
equal young providers (current fellow to 5 years) and
those with more than 20 years experience, at 27% for
both, with lesser numbers in between. When experience was measured by number of cases seen, the majority, 62%, have seen between 1 and 10 cases, with
only 17% having seen greater than 20 cases. Of these
who have seen more than 20 cases, 16 (80%) have
more than 15 years experience. However, of those
with more than 15 years experience, 39% had seen
less than 10 cases. Complete respondent characteristics are detailed in Table 1.

Fig. 1 Number of survey respondents
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Assessment

When evaluating a new JDM diagnosis, 60% use only
history and/or physical exam to screen for calcinosis. If
history and physical exam are negative, 33 (28%) perform imaging studies. Only 11% perform no formal assessment. For presence or suspicion of calcinosis,
radiographs are the initial imaging studies for 88%,
whereas 18% use ultrasound, 17% MRI and 4% computed tomography. If calcinosis is suspected or found,
nearly equal numbers send laboratory studies evaluating calcium and vitamin D levels or no labs at all (45%
each). Once treatment is initiated, 95% use physical
exam to monitor response to therapy (if phenotype is
able to be examined), whereas 70% use imaging. Of
these, plain radiographs are used by 72% of respondents, 15% use MRI, 7% use ultrasound and 4% use
computed tomography.
Classification–Calcinosis phenotype

Two-thirds of respondents believed it was important to
classify the phenotype of calcinosis lesions, with selected
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Table 1 Respondent characteristics
Characteristic

n (%)

Practice scope
Pediatric Rheumatology

114 (96.6)

Adult Rheumatology

1 (0.8)

Combined adult/pediatric Rheumatology

3 (2.5)

Immunology

0 (0)

Practice location
United States

82 (69.5)

Canada

8 (6.8)

Central/South America

9 (7.6)

Europe

16 (13.6)

Asia/India

1 (0.8)

Other (Turkey, Kenya)

1, 1 (0.8)

CARRA Member
Yes

88 (74.6)

No

30 (25.4)

Experience (by years of practice)
Current fellow to 5 years

32 (27.1)

6 to 10 years

30 (25.4)

11 to 15 years

10 (8.5)

16 to 20 years

14 (11.9)

More than 20 years

32 (27.1)

Experience (by # of JDM-calcinosis cases seen)
1 to 10 cases

74 (62.7)

11 to 20 cases

24 (20.3)

21 to 50 cases

18 (15.3)

More than 50

2 (1.7)

Demographic characteristics of all survey respondents included in analysis

rationale of the phenotype affecting treatment type (surgical or medical), treatment aggression or predicting response to treatment. Others listed different expected
morbidity or severity from specific phenotypes. Opponents of classification believed that only the presence of
calcinosis was important, regardless of phenotype. When
asked to rate phenotypes by perceived severity or worse
prognosis, 65% listed universalis, followed by exoskeleton lesions at 57% and tumoral at 42%.

14% regarded absent skin and muscle disease with persistent/refractory calcinosis as active JDM disease. Given
the same scenarios of JDM disease states, respondents
were asked to consider targeted treatment of calcinosis,
independent of therapy prescribed for overall JDM disease activity. The rates of consideration for targeted
treatment were higher in scenarios where skin and
muscle disease activity were decreased and persistence
of calcinosis increased, such that only 56% would consider targeted treatment of calcinosis for active skin and
muscle disease with new calcinosis, but 80% would consider targeted treatment of calcinosis for absent skin and
muscle disease with persistent/refractory calcinosis. Only
43% would consider targeted treatment of calcinosis in
all scenarios, and 9% would not consider targeted therapy in any scenario.
The features of calcinosis lesions that increase the likelihood of targeted therapy, independent of overall JDM
therapy, are more likely to be symptomatic features as
follows: Functional impairment and pain were listed by
97% of respondents, whereas threat to adjacent organs
and recurrent infections were listed by 89 and 80%, respectively. Cosmesis (or psychosocial impact) was listed
by 71%. Only 29% listed calcinosis phenotype, and 8%
listed presence of certain myositis antibodies (listed as
Jo-1, MDA-5 and NXP2) that would increase the likelihood of targeted treatment. When these features were
ranked in order of importance to considering targeted
treatment, functional impairment was ranked highest by
41%, pain ranked second by 40%, and location (as threatening to other organs) third at 37%.
Treatment–Surgical

As first line therapy, only 5% of respondents would refer
for surgical excision. However, if the type of lesion is
amenable to surgical removal, 24% believed every such
case should have a surgical evaluation. Further, 60%
would consider surgery if the lesion(s) caused significant
limitation in mobility or significant pain, but 38% believe
it should be used only if medical therapy failed. Only 4%
believe there is no role for surgery in the management
of calcinosis.

Classification–Disease activity

Treatment–Medical

When asked to characterize “active JDM disease”, nearly
all respondents reported the presence of skin and muscle
disease (defined as presence of rash, nail fold capillary
changes, muscle weakness, elevation of muscle enzymes,
abnormal muscle imaging or EMG findings) as active
JDM disease, opinions that were unchanged by the presence of new or persistent/refractory calcinosis. However,
in the absence of skin and muscle disease, 73% reported
new onset calcinosis as active JDM disease, while only

Therapies were separated into two categories: immunomodulatory and alternative agents, the latter including
drugs with non-immunosuppressive actions, such as altering calcium and phosphorus metabolism. The drugs
in each category and their frequencies of use are displayed in Fig. 2. For the patient developing or presenting
with calcinosis, increasing or adding systemic immunosuppression was first line therapy for 67% of respondents, followed by alternative agents at 13%. A total of
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Fig. 2 Treatment categories and frequency of use among all respondents

14 (13%) would prescribe no specific treatment other
than ‘standard’ therapy for overall JDM activity.
Of the immunomodulatory agents listed, the most frequently used include IV immune globulin (IVIG) by 61
(57%), systemic glucocorticoids by 48% and methotrexate
(specifically for calcinosis) at 40%. Less frequently used
agents include TNF-alpha inhibitors at 25%, rituximab at
19% and abatacept at 11%. Other immunomodulatory
agents that were not listed, but totaled 12%, included anakinra, cyclophosphamide, lenalinomide and sirolimus.
When asked to rank which treatment was perceived to
be most successful against calcinosis, IVIG was ranked first
by 30% of users and second by 26% of users, whereas systemic glucocorticoids were ranked first by 32% of users and
second by 17%. Methotrexate was ranked first by 24% and
second by 9% of respondents. Only mycophenolate, tacrolimus, colchicine and cyclosporine were ranked in the top
three by greater than 10% of respondents; they were listed
second by 20, 12, 12%, and third by 10% respectively.

For alternative agents, bisphosphonates were the
most frequently used (73% of respondents), followed
by calcium channel blockers at 43%. Intravenous sodium thiosulfate was used by 10%, with 14% using
the topical formulation. Other agents not listed that
were used include warfarin and minocycline (totaling
4%). Of note, 20% of respondents have not used any
of the alternative agents.
When ranked according to perceived success against
calcinosis, approximately 60% ranked bisphosphonates
most effective, whereas only 15% ranked calcium channel blockers highest, with an additional 30% ranking second most effective. Although few respondents have used
intravenous sodium thiosulfate, it was perceived as most
effective by three individuals (30%).
Experience differences

Separating experience by those who have seen more or
less than 10 cases, there was no statistically significant
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difference regarding certain assessment and classification
practices (Fig. 3). Roughly equal numbers screen new
diagnoses with imaging or have no formal screening
process. Neither group was more or less likely to consider
new or stable calcinosis as active JDM disease in the absence of skin and muscle disease. Similarly, there was no
difference in the consideration to target treatment against
calcinosis in the absence of skin and muscle activity.
Examining the differences in treatment use, both
groups reported highest use of the same top three immunomodulatory agents: IVIG, systemic glucocorticoids
and methotrexate (Fig. 4). For every agent except local
glucocorticoids, the more experienced respondents reported greater frequency of use, but only colchicine (19/
40 versus 16/67, Pearson chi-square value = 6.348,
p = 0.012) and tacrolimus reached statistical significance
(11/40 versus 8/67, Pearson chi-square value = 4.152,
p = 0.042). Regarding alternative medications, again each
group had the same top two most frequently used
agents: bisphosphonates and calcium channel blockers
(Fig. 5). However, the increased use by more experienced
respondents reached statistical significance for bisphosphonates (37/40 versus 39/64, Pearson chi-square
value = 12.464, p< 0.001), calcium channel blockers (25/
40 versus 20/64, Pearson chi-square value = 9.793,
p = 0.002) and topical sodium thiosulfate (10/30 versus
4/60, Pearson chi-square value = 7.429, p = 0.006).
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Discussion
Calcinosis remains a significant source of morbidity for
many JDM patients, yet it is poorly understood and
lacks uniform treatment approaches compared to other
aspects of JDM. This survey describes the approach
and management of calcinosis by a large number of
pediatric rheumatologists.
The inconsistency in the published literature regarding
therapeutic effectiveness can be explained by the relative
inexperience of physicians and the multitude of different
treatments and treatment scenarios. To date there have
been no published reports comparing therapeutic effectiveness against calcinosis when there is active versus
absent skin and muscle disease. Additionally, not all
published reports list failed therapies prior to success or
concurrent background medications [25]. Part of the discrepancy between number of cases seen and experience
is owed to practice type (size, university affiliation) and
location (city, region, competing practices), which was
not assessed in this survey. However, another potential
contributor is the low percentage of physicians who routinely screen for calcinosis beyond patient history and
physical examination. Based on our results, only 28%
perform additional imaging if history and exam are
negative for calcinosis while 11% perform no formal
screening. This low frequency may be in part due to the
lack of any studied screening methods. It is well-

Fig. 3 Assessment and classification by experience in regards to using imaging to screen for calcinosis if none is apparent by history or physical
exam or if no formal screen is done. Respondent opinion of what constitutes active disease based on the presence or absence of skin/muscle
disease with or without new or refractory calcinosis; and if they would consider targeted treatment against calcinosis irrespective of other disease
activity in the same scenarios
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Fig. 4 Frequency of immunomodulatory use by experience

reported that lesions can be present at diagnosis or
much later [26]. Deeper lesions such as exoskeleton and
universalis phenotypes may not be apparent until a critical
size or mass effect is reached. A lack of screening is
unique to calcinosis when compared to other JDM complications, such as interstitial lung disease, where screening with pulmonary function testing and/or CT imaging is
routinely performed since it is known that even asymptomatic children can have long-term sequelae [27–29].
Also revealing was the expressed understanding of the
role calcinosis plays in active disease and the decision to
treat with therapies targeted at calcinosis. It was clear
that respondents believed the new development of calcinosis with otherwise absent skin and muscle disease represents active disease (73%), however, only 56% would
consider targeted treatment of calcinosis in the most
agreed upon active systemic disease state. Combining
these results provides stark evidence that the majority
(80% combined) prefer to prescribe either systemic immunosuppression or a regimen based on overall JDM
activity with only symptomatic complaints prompting
targeted treatment against calcinosis. Importantly, none

of the above showed significant differences among physicians of different experience levels. The results showed,
however, that experienced physicians may be more willing to use unconventional therapies in the treatment of
this complication. Colchicine and tacrolimus were two
immunomodulatory agents used significantly more by
experienced physicians for treatment of calcinosis, but
they are not mainstays of immunosuppressive treatment
of JDM as a whole. Similarly, although both groups used
alternative agents, experienced physicians were significantly more likely to use bisphosphonates, calcium channel blockers and topical sodium thiosulfate.
Our study has several limitations, including the relatively low response rate for CARRA members. In
addition, the majority of respondents were from North
America and/or CARRA members. Although our intent
to include the pediatric rheumatology bulletin board
community was to obtain a broad scope of practice
across the field, the results cannot be reliably generalized
to the field at-large and perhaps more accurately represent North American and CARRA members with an
interest in JDM. It is possible that many chose not to
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Fig. 5 Frequency of alternative agent use by experience

complete the survey due to a lack of experience with
JDM-associated calcinosis. Thus, an increase number of
respondents with only a few cases seen may not significantly alter the results. Another limitation of our survey
(and others that attempt to describe practice), is that
physicians may answer based on information other than
personal experience and duplicate their responses despite instructions to discourage these types of responses.
Many of the questions were based on hypothetical situations, without complete details that would be present in
case-based surveys. This survey did not directly address
the successes of each physician’s practices, complications
of treatment or cost-effectiveness. Finally, this study is
not intended to recommend specific treatment(s) for
JDM-associated calcinosis but to describe the current
trends in management and highlight the need for increased evidence in assessment and treatment efficacy.

Conclusion
Calcinosis is considered a major source of morbidity,
but often excluded as a metric of clinically active or inactive disease [30], leaving many physicians with limited
experience. There is a lack of formal screening, and most
direct treatment decisions are based on symptomatic
complaints, which is at odds with the moderate numbers
who consider it a component of active disease. Increased

formal research is needed, which could include screening methods, consensus treatment plans that incorporate
disease activity, and the study of combination therapies
in different patient subgroups.
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